Background <p>Limited durability of clinical responses remains a major challenge in chimeric antigen receptor (CAR)-T therapy. CAR-enhancers (CAR-Es), which fuse tumor antigens to interleukin (IL)-2 muteins, provide a targeted strategy to enhance CAR-T persistence and function. It remained unclear whether CAR-Es are effective across distinct tumor contexts, when using patient-derived T cells, or in preventing exhaustion and sustaining persistence. It…
Antigen-IL-2 CAR-enhancer drives CAR-T fate and stemness, enhancing antitumor efficacy across models independent of IL-2R{alpha}
Journal for ImmunoTherapy of Cancer | | Moravej, H., Rakhshandehroo, T., Khan, R. M. M., Rivet, V. M., Marcandalli, E., Mantri, S. R., Taklifi, P., Lee, U.-J., Louis, B. B. V., Munaretto, L. A., Regan, K., Farkash, Z., Berland, L., Gabr, Z., Wolff, A. N., Kowalewski, A., Allen, H. H., Nili, A., Baral, J., Mercadante, D., Fulciniti, M., Jacobson, C. A., Sperling, A. S., Nadeem, O., Nia, H. T., Hemann, M., Munshi, N. C., Rashidian, M.
Topics: blood-cancer, cervical-cancer, immunotherapy
Read the full article at Journal for ImmunoTherapy of Cancer